Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Gain Therapeutics, Inc. (GANX) had Consolidated Net Income/Loss of $-5.61M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-5.61M |
|
-- |
|
-- |
|
$5.35M |
|
$-5.35M |
|
$-0.07M |
|
$-5.43M |
|
$-5.43M |
|
$-5.61M |
|
$-5.61M |
|
|
Consolidated Net Income/Loss |
$-5.61M |
$-5.61M |
|
$-5.35M |
|
$-5.33M |
|
42.23M |
|
42.23M |
|
$-0.13 |
|
$-0.13 |
|
| Balance Sheet Financials | |
$18.22M |
|
$0.05M |
|
$0.52M |
|
$18.74M |
|
$3.89M |
|
$0.27M |
|
$0.84M |
|
$4.73M |
|
$14.01M |
|
$14.01M |
|
$14.01M |
|
42.49M |
|
| Cash Flow Statement Financials | |
$-4.73M |
|
-- |
|
$0.40M |
|
$20.87M |
|
$16.58M |
|
$-4.30M |
|
$0.40M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.69 |
|
-- |
|
-- |
|
0.02 |
|
0.03 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.73M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-40.04% |
|
-40.04% |
|
-29.93% |
|
-39.28% |
|
$0.33 |
|
$-0.11 |
|
$-0.11 |
|